Acasti Pharma

Acasti Pharma, Inc. is a biopharmaceutical company, which engages in the development and commercialization of pharmaceutical applications of its licensed rights for cardiovascular diseases. It focuses on the research of prescription drugs using omega-3, fatty acids derived from krill oil. The company was founded by Henri Harland and Pierre Lemieux on February 1, 2002 and is headquartered in Laval, Canada.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Grace Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of pharmaceutical applications of its licensed rights for cardiovascular diseases. It focuses on the research of prescription drugs using omega-3, fatty acids derived from krill oil. The company was founded by Henri Harland and Pierre Lemieux on February 1, 2002, and is headquartered in Princeton, NJ.

Call to be held on Monday, February 14th at 1:00 PM Eastern Time Call to be held on Monday, February 14th at 1:00 PM Eastern Time

Acasti Pharma Schedules Third Quarter Fiscal 2022 Business Update Conference Call

LAVAL, Québec, Jan. 03, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), today announced that Jan D'Alvise, President and CEO of Acasti, will be presenting at the H.C. Wainwright BioConnect 2022 Conference being held virtually January 10-13, 2022.

Acasti Pharma to Present at the H.C. Wainwright BioConnect 2022 Conference

The stock price of Acasti Pharma Inc (NASDAQ: ACST) increased by 52.25% in the previous trading session. This is why it happened.

Acasti Pharma Stock (ACST): Why The Price Surged

After an Oppenheimer upgrade, shares of ACST stock are soaring higher by more than 25%. Why exactly is the investment firm bullish?

ACST Stock Price Predictions: Why One Analyst Sees Acasti Rocketing to $6

IAMGOLD

Meten Holding Group Ltd.

Are any of these penny stocks on your watchlist right now? The post Best Penny Stocks to Watch as the Market Takes a Bullish Turn appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Best Penny Stocks to Watch as the Market Takes a Bullish Turn

Oppenheimer initiated coverage of Acasti Pharma Inc (NASDAQ: ACST) with an Outperform rating and $6 price target. The analyst sees over 400% upside for the stock.

See Why Acasti Pharma Shares Are Trading Over 20% Higher?

Acasti Pharma Inc (NASDAQ: ACST) has announced interim results from its pivotal pharmacokinetic (PK) bridging study of GTX-104 for Subarachnoid Hemorrhage. Based on an interim analysis of the first 20 of 50 normal healthy subjects, GTX-104 met both primary endpoints for Maximum Concentration (Cmax) on Day 1 and Area Under the Concentration-Time Curve (AUC 0-24 hours) on Day 3, allowing the study to continue under the current infusion protocol to its completion.

Acasti Pharma's Hemorrhage Candidate Shows Encouraging PK Profile In Healthy Volunteers

Bioavailability of GTX-104 compares favorably with the oral formulation of nimodipine; full PK study expected to report out as planned in H1'22 Bioavailability of GTX-104 compares favorably with the oral formulation of nimodipine; full PK study expected to report out as planned in H1'22

Acasti Pharma Announces Interim Data Meets All Primary Endpoints for Pivotal PK Study for GTX-104

LAVAL, Québec, Nov. 24, 2021 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), today announced that Jan D'Alvise, President and CEO of Acasti Pharma, will be participating in the Benzinga All Access event taking place on December 2, 2021.

Acasti Pharma CEO to Participate in the Benzinga All Access Event on December 2nd

LAVAL, Québec, Nov. 12, 2021 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), today announced the annual grant of stock options to its employees, executives and directors.

Acasti Pharma Announces Annual Stock Option Grants

Laval, Quebec--(Newsfile Corp. - November 11, 2021) - Acasti Pharma Inc. (NASDAQ: ACST) (TSXV: ACST) ("Acasti" or the "Company"), today announced that management will present at the Q4 Investor Summit, hosted by the Investor Summit Group, being held virtually on November 16-17, 2021. Jan D'Alvise, President and Chief Executive Officer of Acasti Pharma, is scheduled to present as follows:Event: Q4 Investor SummitDate and Time: Tuesday, November 16 at 3:30 pm Eastern TimeWebcast: https://us06web.zoom.us/webinar/register/WN_Wf9K_2n0QoO3WVYfML50_gA replay of the...

Acasti Pharma To Present At The Q4 Investor Summit on November 16th

Acasti Pharma Inc. (ACST) CEO Jan D'Alvise on Q3 2021 Results - Earning Call Transcript

Call to be held on Wednesday, November 10th at 1:00 PM Eastern Time Call to be held on Wednesday, November 10th at 1:00 PM Eastern Time

Acasti Pharma Schedules Second Quarter Fiscal 2022 Business Update Conference Call

Patents strengthen Acasti's IP portfolio and provide protection through 2036 and 2037, respectively Patents strengthen Acasti's IP portfolio and provide protection through 2036 and 2037, respectively

Acasti Pharma Awarded Composition-of-Matter Patents for GTX-101 in Europe, China and Mexico and for GTX-102 in Japan

Study expected to be completed in the first half of 2022, with the goal to commence the Phase 3 safety study in the second half of 2022 Study expected to be completed in the first half of 2022, with the goal to commence the Phase 3 safety study in the second half of 2022

Acasti Pharma Announces Initiation of Pharmacokinetic Bridging Study for GTX-104, the Company's Lead Drug Candidate for the Treatment of Subarachnoid Hemorrhage

LAVAL, Québec, Sept. 22, 2021 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), today provided a business update and announced that the Nasdaq Stock Market (“Nasdaq”) has confirmed to Acasti that the Company has regained compliance with Nasdaq's minimum bid price requirement.

Acasti Pharma Provides Update Following Acquisition of Grace Therapeutics and Regains Compliance with Nasdaq Listing Standards

LAVAL, Québec, Sept. 14, 2021 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), today announced that it will be presenting at the Oppenheimer Fall Healthcare Summit being held virtually September 20-23, 2021.

Acasti Pharma to Present at the Oppenheimer Fall Healthcare Summit on September 21ˢᵗ

The clinical-stage pharmaceutical company completed its merger with Grace Therapeutics last week.

Why Shares of Acasti Pharma Slumped Tuesday

LAVAL, Québec, Aug. 27, 2021 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti”) (NASDAQ: ACST–TSX-V: ACST), announced today the completion of its previously disclosed acquisition of Grace Therapeutics, Inc. (“Grace”) via merger. The successful completion of the merger positions Acasti to build a premier, late-stage specialty pharma company focused on rare diseases. Based on management's current forecasts, Acasti expects to have enough cash on its balance sheet following the merger to provide at least two years of operating runway. The combined companies will be led by Jan D'Alvise as President and Chief Executive Officer, under the oversight of Acasti's newly elected Board of Directors, comprised of four re-elected directors of Acasti and two Grace nominees newly elected as directors (with a third Grace nominee expected to be nominated prior to the next annual meeting of shareholders). All Grace employees will transition to Acasti and they will continue to maintain a research and development laboratory and commercial presence in North Brunswick, New Jersey.

Acasti Pharma Announces Successful Completion of its Merger with Grace Therapeutics, Inc., Voting Results of its Annual and Special Meeting of Shareholders and Reverse Stock Split

August 4 th webcast replay discussing planned acquisition of Grace Therapeutics  available on the Company's website

Acasti Pharma Provides Business Update for the First Quarter of Fiscal 2022

LAVAL, Québec, July 29, 2021 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST) announces a reminder that it will host a business update conference call on Wednesday, August 4th at 1:00 PM ET to discuss the planned acquisition of Grace Therapeutics, Inc. (“Grace”), a privately held emerging biopharmaceutical company focused on developing innovative drug delivery technologies for the treatment of rare and orphan diseases, as well as topics related to the annual and special meeting of shareholders. Investors and other interested parties are invited to submit questions to management prior to the call's start via email to ACST@crescendo-ir.com.

Reminder: Acasti Pharma to Host Conference Call on August 4th at 1:00 PM ET to Discuss Planned Acquisition of Grace Therapeutics

ConforMIS

Harmony Gold Mining Co Ltd

Northern Dynasty Minerals

Which penny stocks are investors watching with August only a week away? The post Best Penny Stocks to Buy in August?

Best Penny Stocks to Buy in August? 4 for Your Watchlist

All shareholders are strongly encouraged to vote in advance of the August 26, 2021, annual and special meeting of shareholders All shareholders are strongly encouraged to vote in advance of the August 26, 2021, annual and special meeting of shareholders

Acasti Pharma Schedules Conference Call for August 4th at 1:00 PM ET to Discuss Planned Acquisition of Grace Therapeutics

The stock price of Acasti Pharma Inc (NASDAQ: ACST) increased by over 10% pre-market. This is why it happened.

ACST Stock Increases Over 10% Pre-Market: Why It Happened

Cellect Biotechnology Ltd

Aerpio Pharmaceuticals Inc

Check-Cap

Seelos Therapeutics

SCWorx Corp

Biotech penny stocks are in focus; here's 4 to watch right now The post Best Biotech Penny Stocks to Buy in July 2021? 6 For Your Watchlist appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

News for Acasti Pharma Stock (ACST)